Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-829.58%
operating margin TTM
-975.91%
revenue TTM
47.78 Million
revenue per share TTM
0.44$
valuation ratios | |
|---|---|
| pe ratio | -5.81 |
| peg ratio | -0.09 |
| price to book ratio | 3.66 |
| price to sales ratio | 42.57 |
| enterprise value multiple | -5.10 |
| price fair value | 3.66 |
profitability ratios | |
|---|---|
| gross profit margin | 73.28% |
| operating profit margin | -975.91% |
| pretax profit margin | -829.58% |
| net profit margin | -829.58% |
| return on assets | -40.46% |
| return on equity | -52.04% |
| return on capital employed | -57.94% |
liquidity ratios | |
|---|---|
| current ratio | 5.28 |
| quick ratio | 5.28 |
| cash ratio | 0.70 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 259.55 |
| days of payables outstanding | 2,296.83 |
| cash conversion cycle | -2,037.28 |
| receivables turnover | 1.41 |
| payables turnover | 0.16 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.04 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -12.80 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.38 |
| cash per share | 0.74 |
| operating cash flow per share | -0.38 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -12.80 |
| short term coverage ratios | -85.50 |
| capital expenditure coverage ratio | -1,095.65 |
Frequently Asked Questions
When was the last time Aclaris Therapeutics, Inc. (NASDAQ:ACRS) reported earnings?
Aclaris Therapeutics, Inc. (ACRS) published its most recent earnings results on 06-11-2025.
What is Aclaris Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Aclaris Therapeutics, Inc. (NASDAQ:ACRS)'s trailing twelve months ROE is -52.04%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Aclaris Therapeutics, Inc. (ACRS) currently has a ROA of -40.46%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ACRS's net profit margin stand at?
ACRS reported a profit margin of -829.58% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ACRS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 5.28 in the most recent quarter. The quick ratio stood at 5.28, with a Debt/Eq ratio of 0.04.